Panlobular emphysema
ICD-10 J43.1 is a billable code used to indicate a diagnosis of panlobular emphysema.
Panlobular emphysema, a subtype of emphysema, is characterized by the uniform enlargement of the airspaces distal to the terminal bronchioles, leading to a significant loss of lung parenchyma. This condition primarily affects the lower lobes of the lungs and is often associated with alpha-1 antitrypsin deficiency, a genetic disorder that can predispose individuals to lung damage. Clinically, patients may present with progressive dyspnea, chronic cough, and wheezing, which can severely impact their quality of life. As the disease progresses, patients may experience respiratory failure and increased susceptibility to respiratory infections. Diagnostic considerations include pulmonary function tests, imaging studies such as chest X-rays or CT scans, and assessment of alpha-1 antitrypsin levels. Early diagnosis and management are crucial to slowing disease progression and improving patient outcomes.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
J43.1 specifically covers panlobular emphysema, which is characterized by the enlargement of airspaces in the lungs, particularly in patients with alpha-1 antitrypsin deficiency. It is distinct from other emphysema types, such as centrilobular emphysema, which primarily affects the upper lobes.
J43.1 should be used when the clinical presentation and diagnostic findings specifically indicate panlobular emphysema. It is important to differentiate it from other emphysema types, such as J43.0 (centriacinar emphysema) or J43.9 (emphysema, unspecified), based on the patient's history and imaging results.
Documentation for J43.1 should include a detailed clinical history, results from pulmonary function tests, imaging studies showing panlobular changes, and any relevant laboratory tests, such as alpha-1 antitrypsin levels, to support the diagnosis.
